Contact:

Media:
Hazel Davis
Media consultant
Genomic Health
07832234312
hazeldavis@gmail.com

Innovative Oncotype DX® test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients

- *Multi-gene test developed by Genomic Health predicts likelihood of chemotherapy benefit and risk of disease recurrence*

- *Follows recommendations made by the Molecular Pathology Evaluation Panel (MPEP) that the test, in some circumstances, would support decision making in the use of chemotherapy*

[London, 31 May, 2016] Genomic Health UK announced that its Oncotype DX test is now available to the National Health Service Scotland (NHS Scotland) clinicians in health boards throughout the West of Scotland Cancer Network (WoSCaN) to assist them in their decision to prescribe chemotherapy in people with early breast cancer.

This important development follows recommendations made by the Molecular Pathology Evaluation Panel (MPEP), which assesses and evaluates molecular pathology tests for the NHS Scotland.

The Oncotype DX breast cancer test is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer.

"The improved access to a test that allows for a better understanding of individual tumour biology and predicts the likelihood of benefit from chemotherapy is an important step forward for breast cancer patients in Scotland," said Dr Iain Macpherson, Beatson Institute for Cancer Research, Glasgow.

Current criteria used for making chemotherapy treatment decisions in clinical practice can result in substantial overtreatment and unnecessary costs for the healthcare system. Research shows that less than 10% of patients with early-stage breast cancer actually benefit from chemotherapy[1,2] and almost a third of treatment recommendations for UK-based, early-stage breast cancer patients change after the use of the Oncotype DX test.[3]

---

[1] Paik S et al. J Clin Oncol 2006;24:3726-34
[2] Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2012:379;432-444
[3] Holt S, et al. Br J Cancer. 2013 Jun 11; 108(11):2250-8

“Having the information provided by Oncotype DX can give us greater confidence in recommending a treatment plan best suited for an individual patient,” added Dr Sophie Barrett, Beatson West of Scotland Cancer Centre, Glasgow.

A document recently published by the Scottish Government – ‘Beating Cancer – Action and Ambition’ – also mentions the Oncotype DX test and estimates that its use may help around 25 percent of relevant women avoid unnecessary chemotherapy treatment.

The Oncotype DX breast cancer test is incorporated in all major international clinical guidelines and is the only such test recommended for use in clinical practice by NICE (the National Institute of Health and Care Excellence). Since it became available in 2004, the test has been used to personalise treatment decisions in 600,000 patients worldwide.

About Genomic Health

Genomic Health, Inc. is a world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California with UK headquarters in London. For more information, please visit www.GenomicHealth.co.uk. To learn more about Oncotype DX, visit: www.OncotypeDX.com

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to the ability of any potential tests Genomic Health, Inc. may develop to optimize cancer treatment and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies and their impact on reimbursement and adoption; the applicability of clinical study results to actual outcomes; the company's ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's yearly report on Form 10-K for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.